29 results
8-K
EX-99.1
TSVT
2seventy bio Inc
5 Apr 24
Regulation FD Disclosure
9:22am
with multiple myeloma by improving upon the current treatment paradigm, and we remain steadfast in our pursuit of innovation and advancing cell
8-K
EX-99.1
TSVT
2seventy bio Inc
13 Sep 23
Unleash Time 2seventy bio company presentation September 2023
4:03pm
validation emerging In-house clinical drug product manufacturing facility will enable continuous innovation, & facile delivery Vector suspension product
8-K
EX-99.1
TSVT
2seventy bio Inc
14 Aug 23
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
7:02am
in innovation.”
ABECMA CLINICAL, REGULATORY, AND MANUFACTURING UPDATE
2seventy bio, in collaboration with BMS, continues to build on established
8-K
EX-99.1
k9jnlkhvzhe1j2u8at
14 Jun 23
Unleash Time 2seventy bio company presentation June 2023
7:02am
8-K
EX-99.1
fe12jhc647 zvcpdodha
19 May 23
Regulation FD Disclosure
6:07am
8-K
EX-99.1
fz1xczo 14qt
17 May 23
2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio
7:31am
PRE 14A
bm2jl5c
18 Apr 23
Preliminary proxy
5:21pm
POS AM
m0z7bix6
1 Nov 22
Prospectus update (post-effective amendment)
5:10pm
8-K
EX-99.1
hvmev
27 Oct 22
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
7:02am
8-K
EX-99.1
bbo6y vh5
10 Aug 22
Join the Patient Mission Company Presentation August 2022
12:13pm
8-K
EX-99.1
akhlcaq095ztg
10 Aug 22
Other Events
12:00am
424B3
5l5mv6f 382lmw8
12 May 22
Prospectus supplement
5:10pm
424B3
sah4f6jw34z8m
6 May 22
Prospectus supplement
4:18pm
S-1
oebllm cq3qf
28 Apr 22
IPO registration
5:03pm
8-K
EX-99.1
wuqr873jhzedjmoats
8 Apr 22
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
4:17pm
10-K
3ubot
22 Mar 22
Annual report
7:09am